Ideaya Biosciences, INC 10-Q quarterly reports

IDEAYA Biosciences reported a substantial increase in collaboration revenue and a narrowed net loss in Q3 2025, driven by a new licensing agreement and significant pipeline advancements.

IDEAYA Biosciences reported a significant increase in net loss and operating expenses for Q2 2025, driven by accelerated clinical development, while maintaining a strong cash position to fund operations for at least 12 months.

IDEAYA Biosciences and Gilead Sciences expand their collaboration to evaluate IDE397 in combination with Trodelvy in MTAP-deletion NSCLC, alongside a financial update in a recent 10-Q filing.

IDEAYA Biosciences reports a net loss of $144.2 million for the first nine months of 2024, while highlighting clinical progress across its oncology pipeline and a new licensing agreement.

IDEAYA Biosciences reports its second quarter 2024 financial results, highlighting progress in clinical trials and strategic collaborations.

IDEAYA Biosciences has filed an amendment to its quarterly report to include a previously omitted Rule 10b5-1 trading plan by its Chief Scientific Officer.

IDEAYA Biosciences reports a net loss of $39.6 million for the first quarter of 2024, while highlighting significant clinical advancements and a robust cash balance of $941.4 million.